Does Reinforcement of the Staple Line in Left Pancreatectomy Reduce the Rate of Pancreatic Fistula?

Post Operative Pancreatic Fistula Clinical Trial

Official title:

Pancreas Fistula After Distal Pancreatic Resection: Prevention and Treatment in a Randomized Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02149446
• Other study ID #: Surgisis-001
• Status: Recruiting
• Phase: N/A
• First received: May 21, 2014
• Last updated: March 31, 2015
• Start date: April 2014
• Est. completion date: December 2016

Study information

• Verified date: March 2015
• Source: Karolinska University Hospital
• Contact: John Blomberg, MD, PhD
• Email: john.blomberg[@]karolinska.se
• Is FDA regulated: No
• Health authority: Sweden: Medical Products Agency
• Study type: Interventional

Clinical Trial Summary

Dividing pancreas when performing left-sided resections opens the risk for leakage from the divided end of the pancreas. Pancreatic juices could have a severe effect on surrounding abdominal tissues with abscess formation producing systemic inflammation and potential lethal bleeding.

Studies have shown that reinforcement of the staple line when dividing pancreas could reduce the risk of leakage.

Surgisis (COOK Medical) a product already in use for staple line reinforcement in gastric and lung surgery could be used as a reinforcement when stapling pancreas in left sided resections.

In a prospective randomized trial we want to compare Surgisis reinforcement to no reinforcement of stapled division in left sided pancreatic resections.

Primary outcome is pancreatic fistula yes/no.

Description:

Resection of the distal pancreas is often done due to a localized tumor in the body or tail of the pancreas. During later years the mortality after pancreatic resections have been reduced but there still is a substantial risk of severe complications mainly due to leakage from the pancreatic division line which could lead to suffering, longer hospital stay, higher costs and sometimes death. Leakage from a tail resection is probably more common than thought of before. Frequencies of above 30% and even up to 60% have been reported.

The use of somatostatin to reduce the production of pancreatic juice or comparison between stapled division, suturing of the remaining part of the cut pancreas or covering it with glue or available surrounding tissue have not showed significant superiority for any of these methods except for a positive trend regarding the stapling technique. Staple line reinforcement with resorbable mesh has in some studies showed a both negative and positive effect on pancreatic fistula frequency. These studies have been small and non-randomized. A larger randomized single blinded study by Hamilton et al on the other hand showed a significant positive effect on pancreatic fistula frequency after distal pancreatic resection using an absorbable reinforcement device put on the stapler, when only regarding type B and C fistulas as defined by the ISGPF (International Study Group on Pancreatic Fistula) pancreatic leak grading system.

Although all these endeavors the problem of pancreatic fistulas remain and therefore all these operations are concluded with the deposit of one or more drains to the area of the cut pancreas.

There is therefore of importance to continue the work of reducing complications in high risk pancreatic surgery using scientific procedures of high quality as in blinded randomized controlled trials (RCT). The use of reinforced stapling techniques has been used in lung surgery and bariatric surgery to reduce air leakage and strengthen anastomoses. The material used is processed submucosa from the small bowel of the pig, produced by COOK© Medical to fit endoscopic staplers from Ethicon© or Covidien©.

After the promising result from Hamilton et al we plan to study if the reinforcement made by COOK© could reduce the frequency of pancreatic fistula after stapled distal pancreatic surgery in a single blinded RCT.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 2016
• Est. primary completion date: November 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Every patient eligible for pancreatic tail resection.

Exclusion Criteria:

• Not able to read Swedish.

• Not able to understand or accept the concept.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Fistula
• Pancreatic Fistula
• Post Operative Pancreatic Fistula

Intervention

Device:
• Surgisis (C-SLRA-ECH60) made by COOK Medical
Surgisis is extracellular matrix collagen made of the submucosal layer of pigs intestines. Surgisis is gradually remodeled, leaving behind organized tissue

Locations

Country	Name	City	State
Sweden	Dep of Surgical Gastroenterology, Karolinska University Hospital	Stockholm

Sponsors (5)

Lead Sponsor	Collaborator
Karolinska University Hospital	Lund University Hospital, Norrlands University Hospital, Sahlgren´s University Hospital, University Hospital, Linkoeping

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Post operative pancreatic fistula (POPF), Y/N	Pancreatic amylase concentration in any post operative drains. Fistula is diagnosed if pancreatic amylase > 3 times the upper normal limit of pancreatic amylase in plasma on post operative day 3 or later	Participants will be followed for the duration of hospital stay, an expected average of 2 weeks	No
Secondary	POPF healing time	Time from diagnosis to healed pancreatic fistula	Participants will be followed for the duration of hospital stay, an expected average of 2 weeks	No
Secondary	POPF grade according to International Study Group of Pancreatic Fistula (ISGPF) grade A/B/C	Worst POPF grade registered during the observation period.	Participants will be followed for the duration of hospital stay, an expected average of 2 weeks	No
Secondary	Blood chemistry	During the first 7 post operative days each participant will have daily measurements taken from blood samples regarding C-reactive protein, white blood count, pancreatic plasma amylase and from drain fluid regarding pancreas amylase. The participants daily drain volume will also be measured.	The first 7 days after operation	No
Secondary	Morbidity	According to Clavien scoring	Participants will be followed for the duration of hospital stay, an expected average of 2 weeks.	No
Secondary	Mortality		< 90 days after the operation	No
Secondary	Hospital stay	Number of days	Participants will be followed for the duration of hospital stay, an expected average of 2 weeks.	No